GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Return-on-Tangible-Asset

SinoMab BioScience (HKSE:03681) Return-on-Tangible-Asset : -23.84% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. SinoMab BioScience's annualized Net Income for the quarter that ended in Dec. 2024 was HK$-201.83 Mil. SinoMab BioScience's average total tangible assets for the quarter that ended in Dec. 2024 was HK$846.62 Mil. Therefore, SinoMab BioScience's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 was -23.84%.

The historical rank and industry rank for SinoMab BioScience's Return-on-Tangible-Asset or its related term are showing as below:

HKSE:03681' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -64.96   Med: -27.35   Max: -10.57
Current: -22.88

During the past 8 years, SinoMab BioScience's highest Return-on-Tangible-Asset was -10.57%. The lowest was -64.96%. And the median was -27.35%.

HKSE:03681's Return-on-Tangible-Asset is ranked better than
61.52% of 1497 companies
in the Biotechnology industry
Industry Median: -36.98 vs HKSE:03681: -22.88

SinoMab BioScience Return-on-Tangible-Asset Historical Data

The historical data trend for SinoMab BioScience's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SinoMab BioScience Return-on-Tangible-Asset Chart

SinoMab BioScience Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial -10.57 -27.61 -27.09 -26.38 -23.29

SinoMab BioScience Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -28.69 -27.98 -25.11 -21.51 -23.84

Competitive Comparison of SinoMab BioScience's Return-on-Tangible-Asset

For the Biotechnology subindustry, SinoMab BioScience's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's Return-on-Tangible-Asset falls into.


;
;

SinoMab BioScience Return-on-Tangible-Asset Calculation

SinoMab BioScience's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-197.67/( (909.511+788.261)/ 2 )
=-197.67/848.886
=-23.29 %

SinoMab BioScience's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-201.83/( (904.973+788.261)/ 2 )
=-201.83/846.617
=-23.84 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2024) net income data.


SinoMab BioScience  (HKSE:03681) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


SinoMab BioScience Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


SinoMab BioScience Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Liu Wenyi 2201 Interest of corporation controlled by you
Qiang Jing
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Leung Shui On 2201 Interest of corporation controlled by you
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience Headlines

No Headlines